Indication

ALK Positive Non-Small Cell Lung Cancer

1 clinical trial

1 product

Clinical trial

Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive Non-Small Cell Lung Cancer: A Single Arm, Exploratory Trial

Status: Not yet recruiting, Estimated PCD: 2025-06-01

Product